Résumé
We report a case of primary pulmonary hypertension who benefited from oral Sildenafil therapy. Sildenafil, a selective phosphodiesterase type 5 inhibitor which acts as a pulmonary vasodilator, led to an improved clinical condition, exercise performance and haemodynamic parameters which were maintained at 6 months of follow up. Larger trials are warranted.
Sujets)
Administration par voie orale , Adolescent , Relation dose-effet des médicaments , Calendrier d'administration des médicaments , Échocardiographie-doppler , Électrocardiographie/méthodes , Femelle , Études de suivi , Hémodynamique/physiologie , Humains , Hypertension pulmonaire/diagnostic , Inde , Pipérazines/usage thérapeutique , Tomographie par émission de positons/méthodes , Purines , Tests de la fonction respiratoire , Indice de gravité de la maladie , Sulfones , Résultat thérapeutique , Vasodilatateurs/administration et posologieRésumé
Upper extremity deep vein thrombosis (UEDVT) is a rare thrombotic disorder (1-4% or all DVT), but it has a potential for considerable morbidity in the form of pulmonary embolism, persistent upper extremity pain and swelling, superior vena cava syndrome and loss of vascular access. Newer non-invasive methods such as duplex ultrasound and magnetic resonance angiography facilitate early diagnosis. Early catheter directed thrombolysis followed by anticoagulation prevent long-term sequalae.